• Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.33
  • Forecasted Upside: 23,233.33%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.01
+0 (0.00%)
Get New ProSomnus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSA

Analyst Price Target is $2.33
▲ +23,233.33% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ProSomnus in the last 3 months. The average price target is $2.33, with a high forecast of $4.00 and a low forecast of $1.00. The average price target represents a 23,233.33% upside from the last price of $0.01.

This chart shows the closing price for OSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in ProSomnus. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2024Alliance Global PartnersInitiated CoverageBuy$2.00Low
11/10/2023Craig HallumReiterated RatingBuy ➝ Hold$1.00Low
9/26/2023Roth MkmLower TargetBuy ➝ Buy$6.00 ➝ $4.00Low
4/18/2023Roth CapitalReiterated RatingBuyLow
4/3/2023Craig HallumInitiated CoverageBuy$10.00Low
(Data available from 6/23/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ProSomnus logo
ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.
Read More

Today's Range

Now: $0.01
Low: $0.01
High: $0.01

50 Day Range

MA: $0.41
Low: $0.02
High: $0.66

52 Week Range

Now: $0.01
Low: $0.35
High: $5.25

Volume

1,605 shs

Average Volume

65,686 shs

Market Capitalization

$173.94 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of ProSomnus?

The following Wall Street analysts have issued reports on ProSomnus in the last twelve months: Alliance Global Partners, Craig Hallum, and Roth Mkm.
View the latest analyst ratings for OSA.

What is the current price target for ProSomnus?

3 Wall Street analysts have set twelve-month price targets for ProSomnus in the last year. Their average twelve-month price target is $2.33, suggesting a possible upside of 23,233.3%. Roth Mkm has the highest price target set, predicting OSA will reach $4.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $1.00 for ProSomnus in the next year.
View the latest price targets for OSA.

What is the current consensus analyst rating for ProSomnus?

ProSomnus currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OSA.

What other companies compete with ProSomnus?

Other companies that are similar to ProSomnus include Motus GI, ProSomnus, Minerva Surgical, Nyxoah and Stevanato Group. Learn More about companies similar to ProSomnus.

How do I contact ProSomnus' investor relations team?

ProSomnus' physical mailing address is Suite A-2F 555 Shihui Road Songjiang District, Shanghai F4, 201100. The company's listed phone number is 844-537-5337 and its investor relations email address is [email protected]. The official website for ProSomnus is www.ProSomnus.com. Learn More about contacing ProSomnus investor relations.